ONECUT2 Antibody, FITC conjugated

2.1. Primary Uses

• ELISA: Detects ONECUT2 at recommended dilutions (1:1,000–1:4,000) .

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Visualizes ONECUT2 localization in fixed cells .

• Western Blot (WB): Identifies ONECUT2 at ~54–60 kDa in human cell lines (HeLa, HepG2) and tissues .

2.2. Research Context

• Cancer Studies: Used to investigate ONECUT2’s role in hepatocellular carcinoma (HCC) metastasis and prostate cancer drug resistance .

  • In HCC, ONECUT2 upregulates FGF2 and ACLY to promote metastasis, detectable via WB and IHC .

  • In prostate cancer, ONECUT2 drives androgen receptor-independent heterogeneity, validated through chromatin immunoprecipitation (ChIP) .

• Lineage Plasticity: Employed to study ONECUT2’s regulation of stem-like and neuroendocrine phenotypes in breast cancer .

3.1. Validation in Disease Models

3.2. Technical Performance

• Sensitivity: Detects ONECUT2 at concentrations as low as 1 ng/mL in ELISA .

• Specificity: No cross-reactivity with unrelated CUT/homeobox proteins confirmed via peptide blocking .

Supplier Landscape

Handling and Optimization

• Storage: Aliquot upon delivery; protect from light (FITC is light-sensitive) .

• Buffer Compatibility: Compatible with PBS-based buffers; avoid azide-containing solutions for live-cell imaging .

• Titration: Optimal dilutions vary by assay; validate for each experimental system .

Research Implications

The FITC-conjugated ONECUT2 antibody enables dynamic tracking of ONECUT2 expression in real-time assays, such as:

• Drug Response Studies: Monitoring ONECUT2 suppression by FGFR1/ACLY inhibitors in HCC models .

• Lineage Tracing: Resolving ONECUT2-driven heterogeneity in prostate and breast cancers .